Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hesham Mohamed
A Phase 2 Safety Study of Accelerated Elotuzumab Infusion, Over Less Than 1 H, in Combination With Lenalidomide and Dexamethasone, in Patients With Multiple Myeloma
American Journal of Hematology
Hematology
The Expression and Prognostic Value of Stem Cell Markers Bmi-1, HESC5:3, and HES77 in Human Papillomavirus–positive and –Negative Oropharyngeal Squamous Cell Carcinoma
Tumor Biology
Medicine
Cancer Research
Related publications
Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma
Hematology
Hematology
Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Enduring Efficacy and Tolerability of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma ( GEN 503): Final Results of an Open‐label, Phase 1/2 Study
British Journal of Haematology
Hematology
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone
Internal Medicine
Internal Medicine
Medicine
Lenalidomide Plus Dexamethasone Is More Effective Than Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Regardless of Prior Thalidomide Exposure
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib
British Journal of Haematology
Hematology
Pcn88 - Net Impact Analysis of Ixazomib in Combination With Lenalidomide and Dexamethasone in the Treatment of Adults With Multiple Myeloma for Quebec
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
